New pill for macular degeneration enters first human tests

NCT ID NCT07330674

Recruiting now Disease control Sponsor: Aptabio Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study tests an oral drug called ABF-101 in healthy adults and people with age-related macular degeneration (AMD). The main goal is to check safety and how the body processes the drug. About 68 participants will take either ABF-101 or a placebo to see if it is well-tolerated.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ABF-101 (oral drug)
What this could lead to: If this early trial shows ABF-101 is safe, it could lead to a new oral treatment option for age-related macular degeneration.
What could go wrong: This is a very early Phase 1 study with only 68 participants, focused on safety. It is too soon to know if ABF-101 will effectively treat AMD or have serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION (ARMD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

age-related macular degeneration macular degeneration

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

Dallas Clinical Research Unit
RECRUITING

Dallas, Texas, 75247, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.